Generics

Mylan has received the FDA's OK for generic Canasa, which had a market value of roughly $263 million.

The FDA has approved Glenmark's generics DermOtic Oil and Westcort ointment, which had a market value of about $18.1 million, and $11.1 million respectively.

Novadoz has received FDA clearance for generic Rapaflo, which is indicated for the symptomatic relief in men experiencing the condition benign prostatic hyperplasia.

Sandoz and Gan & Lee plan to bring biosimilar versions of glargine, lispro and aspart to market.

Hikma is introducing its generic Ampyra, which had a market value of about $543 million in 2017.

Lupin has received the Food and Drug Administration's OK for generic Onfi, and tentative nod for generic Adcirca, with a value of $601.2 million and $503.8 million, respectively.

Vitruvius recently received the FDA's approval for generic Amicar, which has a market value of roughly $26.2 million.

The Food and Drug Administration has approved Mylan's generic Lialda, which had a market value of roughly $842 million for the year ended Oct. 31, according to IQVIA data.